Compare MXE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXE | INTS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.7M | 13.7M |
| IPO Year | 1994 | 2021 |
| Metric | MXE | INTS |
|---|---|---|
| Price | $13.13 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.67 |
| AVG Volume (30 Days) | 2.5K | ★ 19.9K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.57 | $0.22 |
| 52 Week High | $14.30 | $8.06 |
| Indicator | MXE | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 45.93 |
| Support Level | $12.83 | $3.10 |
| Resistance Level | $13.60 | $4.17 |
| Average True Range (ATR) | 0.30 | 0.29 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 71.31 | 58.00 |
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek high total return through capital appreciation and current income. It invests in equity securities, convertible securities and debt securities and may also invest in other securities such as capital development certificates, real estate investment trusts, mutual funds, exchange traded funds, preferred stocks, rights and warrants.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.